Skip to content
Sign in

EBS · NYSE

Emergent BioSolutions (EBS) Stock Price & Fundamentals

$890.37+0.10%+$0.89End-of-day price as of Oct 9, 2026

Emergent BioSolutions (EBS) closed at $890.37 on Oct 9, 2026, up 0.10% from the previous close of $889.48.

Share price, past year

1Y +39.45%

52-week range $638.47 – $897.38. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$890.37
Sep 30, 2026$885.45
Aug 31, 2026$836.84
Jul 31, 2026$823.96
Jun 30, 2026$837.62
May 29, 2026$813.24
Apr 30, 2026$825.72
Mar 31, 2026$787.99
Feb 27, 2026$754.48
Jan 30, 2026$762.56
Dec 31, 2025$714.50
Nov 28, 2025$657.15
Oct 31, 2025$659.49

Key statistics

Market cap
$45.68B
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
$770.20M
Net income (TTM)
−$176.80M
Shares outstanding
51.3M
Dividend yield
—
52-week range
$638.47 – $897.38

Emergent BioSolutions's market cap is $45.68B, based on a share price of $890.37 and 51.3M shares outstanding as of Jun 30, 2026.

Financials

Emergent BioSolutions reported revenue of $742.90M for fiscal 2025, down 28.81% from fiscal 2024.

Emergent BioSolutions earned net income of $52.60M in fiscal 2025, a net margin of 7.1%.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Emergent BioSolutions annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$742.90M−28.8%$52.60M7.1%$0.93$156.80M
FY2024ended Dec 31, 2024$1.04B−0.5%−$190.60M−18.3%−$3.60$35.80M
FY2023ended Dec 31, 2023$1.05B−6.1%−$760.50M−72.5%−$14.85−$257.90M
FY2022ended Dec 31, 2022$1.12B−37.0%−$211.60M−18.9%−$4.22−$149.90M
FY2021ended Dec 31, 2021$1.77B+14.0%$219.50M12.4%$4.06$96.10M
FY2020ended Dec 31, 2020$1.56B+40.6%$305.80M19.7%$5.68$395.00M
FY2019ended Dec 31, 2019$1.11B+41.4%$54.50M4.9%$1.04$101.10M
FY2018ended Dec 31, 2018$782.40M+39.5%$62.70M8.0%$1.22−$30.30M
FY2017ended Dec 31, 2017$560.90M+14.8%$82.60M14.7%$1.71$153.30M
FY2016ended Dec 31, 2016$488.80M—$51.80M10.6%$1.13−$21.60M
Emergent BioSolutions quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$234.30M−$180.20M−$3.49
Q1 FY2026ended Mar 31, 2026$156.10M$6.80M$0.07
Q4 FY2025ended Dec 31, 2025$148.70M−$54.60M—
Q3 FY2025ended Sep 30, 2025$231.10M$51.20M$0.91
Q2 FY2025ended Jun 30, 2025$140.90M−$12.00M−$0.22
Q1 FY2025ended Mar 31, 2025$222.20M$68.00M$1.19
Q4 FY2024ended Dec 31, 2024$194.70M−$31.30M—
Q3 FY2024ended Sep 30, 2024$293.80M$114.80M$2.06

Company profile

Name
Emergent BioSolutions Inc.
Ticker
EBS
Exchange
NYSE
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
300 Professional Dr, Gaithersburg, MD 20879
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001367644

Recent SEC filings

Frequently asked questions

What is Emergent BioSolutions's stock price?

Emergent BioSolutions (EBS) closed at $890.37 on Oct 9, 2026, up 0.10% from the previous close of $889.48.

What is Emergent BioSolutions's market cap?

Emergent BioSolutions's market cap is $45.68B, based on a share price of $890.37 and 51.3M shares outstanding as of Jun 30, 2026.

How much revenue does Emergent BioSolutions make?

Emergent BioSolutions reported revenue of $742.90M for fiscal 2025, down 28.81% from fiscal 2024.

Does Emergent BioSolutions pay a dividend?

Emergent BioSolutions's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Emergent BioSolutions Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures